CorrespondenceMetastatic basal cell carcinoma with neuroendocrine differentiation: complete response to cemiplimab-Reference-Cited by-同舟云学术

CorrespondenceMetastatic basal cell carcinoma with neuroendocrine differentiation: complete response to cemiplimab

Published:2024-03-18 Issue:9 Volume:49 Page:1060-1062
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Marti-Marti Ignasi¹,Puig Susana¹²³^ORCID,Albero-González Raquel⁴,Masferrer Emili⁵,Iglesias Pablo¹,Pérez-Anker Javiera¹^ORCID,Serra-García Laura¹,Tarroch Xavier⁶,Curcó Neus⁵,Toll Agustí¹

Affiliation:

1. Dermatology Department, Hospital Clínic, Universitat de Barcelona , Barcelona , Spain

2. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) , Barcelona , Spain

3. Centro de Investigación en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III , Barcelona , Spain

4. Pathology Department, Hospital Clínic, Universitat de Barcelona , Barcelona , Spain

5. Department of Dermatology, Hospital Universitari Mútua Terrassa, Barcelona, Spain

6. Department of Pathology, Hospital Universitari Mútua Terrassa , Barcelona , Spain

Abstract

We report a patient with a metastatic basal cell carcinoma with neuroendocrine differentiation who responded well to cemiplimab but not to previous therapies. The different histological variants could determine treatment response.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llae099/57927282/llae099.pdf

Reference5 articles.

1. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011;Wysong;JAMA Dermatol,2013

2. Neuroendocrine differentiation in basal cell carcinoma;Houcine;J Immunoassay Immunochem,2017

3. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies;Jacobsen;JAMA Dermatol,2016

4. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors;Lewis;Ann Oncol,2024

5. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial;Stratigos;Lancet Oncol,2021